Graphite Bio presents preclinical GPH102 data for beta-thalassemia; HDR rates up to 40%

LENZ Therapeutics, Inc.

Preclinical gene replacement data for GPH102 presented at ASGCT; HDR rates up to 40% in sickle cell HSPCs restoring HbA expression.
GPH102 aims to replace mutated beta-globin gene to treat beta-thalassemia, targeting IND submission by mid-2024.
Encore poster for GPH101 Phase 1/2 CEDAR trial for sickle cell disease also presented at ASGCT.
Data accepted for encore presentation at EHA 2022 Hybrid Congress in June.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.